These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30239803)

  • 1. Clinical, Biochemical, and Genetic Characteristics of "Nonclassic" Apparent Mineralocorticoid Excess Syndrome.
    Tapia-Castillo A; Baudrand R; Vaidya A; Campino C; Allende F; Valdivia C; Vecchiola A; Lagos CF; Fuentes CA; Solari S; Martínez-Aguayo A; García H; Carvajal CA; Fardella CE
    J Clin Endocrinol Metab; 2019 Feb; 104(2):595-603. PubMed ID: 30239803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Cortisol and Cortisone as Potential Biomarkers of Partial 11β-Hydroxysteroid Dehydrogenase Type 2 Deficiency.
    Carvajal CA; Tapia-Castillo A; Valdivia CP; Allende F; Solari S; Lagos CF; Campino C; Martínez-Aguayo A; Vecchiola A; Pinochet C; Godoy C; Iturrieta V; Baudrand R; Fardella CE
    Am J Hypertens; 2018 Jul; 31(8):910-918. PubMed ID: 29617893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [From gene to disease; 'apparent mineralocorticoid excess' syndrome, a syndrome with an apparent excess of mineral corticoids].
    Levtchenko EN; Deinum J; Knoers NV; Hermus AR; Monnens LA; Lenders JW
    Ned Tijdschr Geneeskd; 2007 Mar; 151(12):692-4. PubMed ID: 17447595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of exosomal miR-192-5p and miR-204-5p in subjects with nonclassic apparent mineralocorticoid excess.
    Tapia-Castillo A; Guanzon D; Palma C; Lai A; Barros E; Allende F; Vecchiola A; Fardella CE; Salomón C; Carvajal CA
    J Transl Med; 2019 Nov; 17(1):392. PubMed ID: 31775784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent mineralocorticoid excess syndrome: an overview.
    Palermo M; Quinkler M; Stewart PM
    Arq Bras Endocrinol Metabol; 2004 Oct; 48(5):687-96. PubMed ID: 15761540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classic and Nonclassic Apparent Mineralocorticoid Excess Syndrome.
    Carvajal CA; Tapia-Castillo A; Vecchiola A; Baudrand R; Fardella CE
    J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31909799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Urinary Exosomal HSD11B2 mRNA Expression: A Useful Novel Tool for the Diagnostic Approach of Dysfunctional 11β-HSD2-Related Hypertension.
    De Santis D; Castagna A; Danese E; Udali S; Martinelli N; Morandini F; Veneri M; Bertolone L; Olivieri O; Friso S; Pizzolo F
    Front Endocrinol (Lausanne); 2021; 12():681974. PubMed ID: 34497581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apparent mineralocorticoid excess syndrome: report of one family with three affected children.
    Al-Harbi T; Al-Shaikh A
    J Pediatr Endocrinol Metab; 2012; 25(11-12):1083-8. PubMed ID: 23329753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess.
    Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A
    J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent Mineralocorticoid Excess by a Novel Mutation and Epigenetic Modulation by HSD11B2 Promoter Methylation.
    Pizzolo F; Friso S; Morandini F; Antoniazzi F; Zaltron C; Udali S; Gandini A; Cavarzere P; Salvagno G; Giorgetti A; Speziali G; Choi SW; Olivieri O
    J Clin Endocrinol Metab; 2015 Sep; 100(9):E1234-41. PubMed ID: 26126204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent mineralocorticoid excess (AME) syndrome.
    Parvez Y; Sayed OE
    Indian Pediatr; 2013 Apr; 50(4):416-8. PubMed ID: 23665601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent mineralocorticoid excess syndrome in a Brazilian boy caused by the homozygous missense mutation p.R186C in the HSD11B2 gene.
    Coeli FB; Ferraz LF; Lemos-Marini SH; Rigatto SZ; Belangero VM; de-Mello MP
    Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1277-81. PubMed ID: 19169481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apparent mineralocorticoid excess caused by novel compound heterozygous mutations in HSD11B2 and characterized by early-onset hypertension and hypokalemia.
    Fan P; Lu YT; Yang KQ; Zhang D; Liu XY; Tian T; Luo F; Wang LP; Ma WJ; Liu YX; Zhang HM; Song L; Cai J; Lou Y; Zhou XL
    Endocrine; 2020 Dec; 70(3):607-615. PubMed ID: 32816205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency.
    Yau M; Haider S; Khattab A; Ling C; Mathew M; Zaidi S; Bloch M; Patel M; Ewert S; Abdullah W; Toygar A; Mudryi V; Al Badi M; Alzubdi M; Wilson RC; Al Azkawi HS; Ozdemir HN; Abu-Amer W; Hertecant J; Razzaghy-Azar M; Funder JW; Al Senani A; Sun L; Kim SM; Yuen T; Zaidi M; New MI
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11248-E11256. PubMed ID: 29229831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent mineralocorticoid excess in Israel: a case series and literature review.
    Lebel A; Ben Shalom E; Mokatern R; Halevy R; Zehavi Y; Magen D
    Eur J Endocrinol; 2024 May; 190(5):347-353. PubMed ID: 38652803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature.
    Adamidis A; Cantas-Orsdemir S; Tsirka A; Abbott MA; Visintainer P; Tonyushkina K
    Pediatr Endocrinol Rev; 2019 Mar; 16(3):335-358. PubMed ID: 30888125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel metabolomic profile of subjects with non-classic apparent mineralocorticoid excess.
    Tapia-Castillo A; Carvajal CA; López-Cortés X; Vecchiola A; Fardella CE
    Sci Rep; 2021 Aug; 11(1):17156. PubMed ID: 34433879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
    Whorwood CB; Stewart PM
    J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
    Ferrari P; Lovati E; Frey FJ
    J Hypertens; 2000 Mar; 18(3):241-8. PubMed ID: 10726708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?
    Palermo M; Delitala G; Sorba G; Cossu M; Satta R; Tedde R; Pala A; Shackleton CH
    J Endocrinol Invest; 2000; 23(7):457-62. PubMed ID: 11005270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.